BioSite Triage Becomes The First BNP Test To Receive A CLIA Waiver

BioSite plans to market its Triage BNP test to the 55,000 physician practices that most often treat heart failure patients after becoming the first BNP test manufacturer to receive a CLIA waiver from FDA